BR0311702A - Uso de um agente redutor de coágulo e kit comercial para reduzir a hidrocefalia obstrutiva - Google Patents

Uso de um agente redutor de coágulo e kit comercial para reduzir a hidrocefalia obstrutiva

Info

Publication number
BR0311702A
BR0311702A BR0311702-2A BR0311702A BR0311702A BR 0311702 A BR0311702 A BR 0311702A BR 0311702 A BR0311702 A BR 0311702A BR 0311702 A BR0311702 A BR 0311702A
Authority
BR
Brazil
Prior art keywords
reducing agent
commercial kit
clot
reduce
clot reducing
Prior art date
Application number
BR0311702-2A
Other languages
English (en)
Inventor
Jay M Meythaler
Winfield S Fisher
Original Assignee
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Research Foundation filed Critical Uab Research Foundation
Publication of BR0311702A publication Critical patent/BR0311702A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A61K38/166—Streptokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"USO DE UM AGENTE REDUTOR DE COáGULO E KIT COMERCIAL PARA REDUZIR A HIDROCEFALIA OBSTRUTIVA". Um processo para reduzir a obstrução da vazão do líquido cérebro-espinhal inclui a administração de uma dose terapêutica de um agente redutor de coágulo para um indivíduo tendo pré-condições ou sintomas da hidrocefalia obstrutiva. A dose é mantida dentro do indivíduo por um período de tempo suficiente para reduzir a obstrução da vazão do líquido cérebro-espinhal. O agente redutor de coágulo inclui um ativador de plasminogênio, um agente desfibrinogênico, um anticoagulante, um inibidor de plaquetas e uma combinação dos mesmos. Um kit comercial é provido, contendo um agente redutor de coágulo, um dispositivo de administração, junto com instruções para uso do kit.
BR0311702-2A 2002-06-03 2003-06-03 Uso de um agente redutor de coágulo e kit comercial para reduzir a hidrocefalia obstrutiva BR0311702A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38497302P 2002-06-03 2002-06-03
PCT/US2003/017271 WO2003101281A2 (en) 2002-06-03 2003-06-03 Method for reducing obstructive hydrocephalus

Publications (1)

Publication Number Publication Date
BR0311702A true BR0311702A (pt) 2005-03-08

Family

ID=29712115

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0311702-2A BR0311702A (pt) 2002-06-03 2003-06-03 Uso de um agente redutor de coágulo e kit comercial para reduzir a hidrocefalia obstrutiva

Country Status (9)

Country Link
US (1) US20060210548A1 (pt)
EP (1) EP1513548A2 (pt)
JP (1) JP2005533033A (pt)
AU (1) AU2003243358A1 (pt)
BR (1) BR0311702A (pt)
CA (1) CA2488238A1 (pt)
MX (1) MXPA04012147A (pt)
NZ (1) NZ537016A (pt)
WO (1) WO2003101281A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9694166B2 (en) 2002-03-26 2017-07-04 Medtronics Ps Medical, Inc. Method of draining cerebrospinal fluid
JP7393006B2 (ja) * 2018-01-25 2023-12-06 ペンタファーム アーゲー フィブリノーゲン検査

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5523292A (en) * 1992-10-14 1996-06-04 Schwartz; Robert Method of preventing restenosis following coronary angioplasty
US6056958A (en) * 1994-12-09 2000-05-02 Dupont Pharmaceuticals Method of treatment of arterial and venous thromboembolic disorders
EP1080218A1 (en) * 1998-05-27 2001-03-07 University of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixanol gradient
CA2345641A1 (en) * 1998-09-28 2000-04-06 Merck & Co., Inc. A method for treating inflammatory diseases by administering a thrombin inhibitor
EP1324800B1 (en) * 2000-09-11 2008-07-02 CSF Dynamics A/S A fluid shunt system for the treatment of hydrocephalus
WO2002064022A2 (en) * 2001-02-14 2002-08-22 Duke University Therapy for cerebral vasospasm
US6683066B2 (en) * 2001-09-24 2004-01-27 Yanming Wang Composition and treatment method for brain and spinal cord injuries
AU2003230777A1 (en) * 2002-03-29 2003-10-13 The Johns Hopkins University Intraventricular hemorrhage thrombolysis

Also Published As

Publication number Publication date
WO2003101281A2 (en) 2003-12-11
MXPA04012147A (es) 2005-09-21
NZ537016A (en) 2008-06-30
AU2003243358A1 (en) 2003-12-19
CA2488238A1 (en) 2003-12-11
JP2005533033A (ja) 2005-11-04
US20060210548A1 (en) 2006-09-21
EP1513548A2 (en) 2005-03-16
WO2003101281A3 (en) 2004-09-10

Similar Documents

Publication Publication Date Title
BRPI0311323B8 (pt) composto inibidor de c-aril glicosídeo sglt2, composição farmacêutica e combinação
BR9812484A (pt) Terapia combinada para erradicação de hcv-rna detectável em pacientes com infecção crÈnica por hepatite c
BRPI0308663B8 (pt) uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas
BR0111196A (pt) Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus
BR0307050A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina d2, para o tratamento de congestão nasal, para o tratamento de asma alérgica, e para o tratamento de rinite alérgica, sal farmaceuticamente aceitável, e, uso de um composto ou sal
BR0014003A (pt) Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra
CR7152A (es) Un inhibidor de pde4 y un agente de anticolinergico en combinacion para tratar enfermedades obstructivas de vias respiratorias.
AR045304A1 (es) Sistema de implante dental
BR0109912A (pt) Novas combinações antelmìnticas
BR9910391A (pt) Válvula medicinal com caracterìsticas de escoamento positivo
BR9913742A (pt) Inibidores de fator viia
BR0101264A (pt) Derivados de diazepan ou seus sais
RS52825B (en) PROCEDURES FOR THE TREATMENT OF DISORDERS OR DISEASES RELATED TO HYPERLIPIDEMIA AND HYPERHOLESTEROLEMIA WITH MINIMIZATION OF ADVERSE EFFECTS
BR9807653A (pt) Dispositivo aperfeiçoado para transferência de massa
BR9810520A (pt) Inibidor do fator xa isolado ou em combinação com um anti-agregador plaquetário, contra a trambose arterial
AR035987A1 (es) Uso de un compuesto inhibidor de la pde 4 para la manufactura de un medicamento y el medicamento para tratar asma inducida por ejercicio
NO20020056D0 (no) Fremgangsmåte og system for anvendelse ved behandling av en pasient med et hvilket som helst medikament for å optimalisereterapien og forhindre en negativ medikamentrespons
BR0112212A (pt) Uma combinação de inibidores de fbpase e agentes antidiabéticos úteis para o tratamento de diabetes
BRPI0519016A2 (pt) agente preventivo ou terapÊutico para distérbios do sono, uso de uma droga, e, mÉtodo para prevenÇço e/ou tratamento de distérbios do sono
EE03420B1 (et) Farmatseutiline kompositsioon maania ja bipolaarse häire raviks
BR0208694A (pt) Uso de inibidores de cox-2 seletivos para tratamento de incontinência urinária
BR9915546A (pt) Terapia de combinação de ribavirin- interferon alfa para a erradiação de hcv-rna detectável em pacientes tendo infecção por hepatite c crÈnica
BR0206549A (pt) Uso de flumazenil na produção de uma droga para o tratamento de dependência de álcool
BR0311702A (pt) Uso de um agente redutor de coágulo e kit comercial para reduzir a hidrocefalia obstrutiva
BRPI0408944A (pt) método para fornecer um benefìcio de redução de esteróide com um inibidor de ciclooxigenase-2 e composições com este

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A,5A,6A E 7A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2064 DE 27/07/2010.